

Date: 7th August, 2023

BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404 National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.
Symbol: MARKSANS

PRESS RELEASE

Dear Sirs,

Enclosed herewith kindly find a Press Release of the Company.

For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

Enclosed as above.

www.marksanspharma.com



Marksans announces completion of US FDA Post-marketing Adverse Drug Experience (PADE) inspection

The Company hereby announces that the United State Food and Drug Administration (US FDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection. The inspection closed with two observations.

The inspection was conducted at its Goa, Verna manufacturing facility from 31st July, 2023 to 4th August, 2023. The inspection included comprehensive scrutiny of practices and procedures for reporting of adverse events of Marksans' marketed products.

We will submit corrective and preventive action plan (CAPA) to the US FDA in the stipulated time frame.

About Marksans Pharma

Marksans Pharma Ltd. (www.marksanspharma.com) headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The company is marketing these products globally.



www.marksanspharma.com